While AstraZeneca's (NYSE: AZN) stock delivered solid returns in 2013, the company is still in the middle of a multiyear turnaround. With patent expirations just around the corner, and a pipeline that has failed to deliver a new blockbuster therapy in recent years, AstraZeneca's strategy has become the most important factor in its long-term survival in the pharmaceutical industry.
This massive company has several moving parts. But in the video below, Motley Fool analyst Max Macaluso focuses on just one red light and one green light that investors should consider before buying shares today.
So, what's the top stock pick for 2014?
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.